Terms and conditions of use

Abcam is subject to the UK City Code on Takeover and Mergers; this site is provided to be compliant with the UK’s stock exchange AIM Rule 26. By using this website you agree to be bound by the terms below.

Statements/opinions/views

Any statements, opinions or estimates on this website constitute the reasonable belief of Abcam but are subject to change without notice. Abcam is not rendering legal or accounting advice through any material; readers should contact their legal and accounting professionals for such information.

Third party data

Some information contained on this site has been obtained from other third party sources and has not been independently verified by Abcam.

Accuracy of information

Abcam makes no representations as to the accuracy or the completeness of any of the information on this site. Neither Abcam nor any other party involved in or related to compiling, computing or creating the data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof) and all such parties hereby expressly disclaim, to the maximum extent permitted by law and regulation, any and all responsibility or liability as to the accuracy, completeness or reasonableness of the information provided.

Forward looking statements

This website may contain forward-looking statements, which are based upon current expectations and assumptions regarding anticipated developments and other factors affecting the Abcam group. They are not historical facts, nor are they guarantees of future performance. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These forward-looking statements speak only as of the date of the relevant document or page. You should not place undue reliance on such statements.

General

Some content of this website may be restricted by law and persons using it should inform themselves about and observe any relevant restrictions.

The information on this website does not constitute an invitation or inducement to engage in investment activity. Similarly, it does not constitute or form part of any offer or invitation to sell or issue or any solicitation of any offer to purchase or subscribe for any securities of Abcam in any jurisdiction, nor shall it (nor any part of it) or the fact of its distribution form the basis of, or be relied upon in connection with, or act as any inducement to enter into, any contract or investment decision in relation thereto. Users of the site who intend to purchase or subscribe for shares in Abcam are reminded that any such purchase or subscription must only be made solely on the basis of information contained in a formal offer document or circular relating to Abcam in its final form.

Abcam ordinary shares have not been registered under the US Securities Act of 1933, as amended (the ‘Securities Act’) or any state securities laws and may not be offered or sold in the United States absent a registration statement or an applicable exemption from the registration requirements of the Securities Act and any applicable state securities laws.

About Abcam

Abcam is a producer and marketer of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level which is essential in a wide range of fields including drug discovery, diagnostics, and basic research.

Read more +

Abcam Products

As an innovator in reagents and tools, Abcam offers highly validated binders and assays to address important targets in critical biological pathways.

Read more +

Investor Information

Abcam is listed on the AIM market of the London Stock Exchange under the ticker ABC, and our investors' centre includes a range of information on our company, including our news, financial reports and investor contacts

Read more +

Abcam News

We provide updates on our commercial and financial progress through regular press releases which can be accessed through the Company's media centre.

Read more +